Etelcalcetide

Etelcalcetide (Parsabiv) is a synthetic peptide that works the calcium/parathyroid system from the opposite direction of the anabolic bone hormones already covered on this site — it's a calcimimetic, tricking the parathyroid gland into reading blood calcium as higher than it is, which lowers PTH. FDA-approved in 2017 on the strength of three real Phase 3 trials in more than 1,700 hemodialysis patients, it remains the only intravenous calcimimetic on the market.

A different angle on the same calcium system

Etelcalcetide is a synthetic peptide — seven D-amino acids in a linear chain, with a D-cysteine linked by a disulfide bond to an L-cysteine — that acts as a calcimimetic: an agonist at the calcium-sensing receptor (CaSR) on the parathyroid gland's chief cells.³ Activating that receptor is how the body normally senses "there's enough calcium in the blood already" and dials parathyroid hormone (PTH) production down. In patients on hemodialysis, damaged kidneys disrupt that feedback loop, PTH climbs chronically, and the result — secondary hyperparathyroidism — pulls calcium and phosphate out of bone, driving the vascular calcification, fracture risk and cardiovascular disease that make chronic kidney disease so dangerous long-term. That puts etelcalcetide in an interesting position relative to teriparatide, abaloparatide and PTH(1-84) already on this site: those three are PTH analogs, deliberately raising PTH signaling to build bone. Etelcalcetide does the opposite job, in a different disease context — lowering PTH that has already climbed too high — while calcitonin, also covered here, lowers blood calcium directly through an entirely separate receptor. Unusually for its structural class, etelcalcetide's D-cysteine doesn't just sit near the receptor electrostatically the way most calcimimetics do — it forms an actual covalent disulfide bond with cysteine 482 on the receptor's extracellular domain, a distinct binding chemistry from earlier calcimimetics.³

Three Phase 3 trials, more than 1,700 patients

Two parallel, randomized, placebo-controlled Phase 3 trials in a combined 1,023 hemodialysis patients with moderate-to-severe secondary hyperparathyroidism found etelcalcetide reduced serum PTH by more than 30% from baseline in 74.7% of patients, versus 8.9% on placebo, over 26 weeks (Block, Bushinsky, Cunningham, et al., JAMA 2017;317(2):146-155, PMID 28097355, DOI: 10.1001/jama.2016.19456).¹ A third, separately published head-to-head trial randomized 683 hemodialysis patients to intravenous etelcalcetide or oral cinacalcet and found etelcalcetide not just non-inferior but statistically superior on the same >30% PTH-reduction endpoint (68.2% vs 57.7%) and on a stricter >50% reduction endpoint (52.4% vs 40.2%) (Block, Bushinsky, et al., JAMA 2017;317(2):156-164, PMID 28097356).² That is a real, published, three-trial evidence base in a combined population above 1,700 — not a single pivotal study, and not company-summary numbers taken at face value.

How it compares to cinacalcet, the oral calcimimetic that came first

Cinacalcet (Sensipar), approved in 2004, was the first calcimimetic on the market — a small-molecule oral pill, not a peptide, taken daily. Etelcalcetide arrived over a decade later as a genuinely different delivery model: an IV push given three times a week by dialysis staff, timed to the end of each hemodialysis session, rather than a pill the patient has to remember to take at home. That difference turns out to matter clinically, not just logistically — in the head-to-head trial above, a large share of patients switched to etelcalcetide specifically because they were intolerant of or non-adherent to oral cinacalcet, and etelcalcetide produced somewhat less nausea and vomiting than cinacalcet in comparative data (11.0% vs 14.3% nausea; 9.4% vs 14.9% vomiting).² The trade-off is a higher rate of hypocalcemia with etelcalcetide than with cinacalcet — a real, documented difference, not a wash in either direction.

The real risk: hypocalcemia

This is the actual safety story with etelcalcetide, and it is precisely why it is given only in a dialysis clinic, with calcium checked before each dose and staff on hand — not a drug suited to home self-administration regardless of how convenient thrice-weekly IV dosing sounds next to a daily pill.

Current status

Etelcalcetide has a slightly unusual corporate history worth noting: it was discovered by KAI Pharmaceuticals, a small biotech, as KAI-4169 (also called velcalcetide) — Amgen acquired KAI Pharmaceuticals outright in July 2012, while the drug was still in Phase 2, and carried it through Phase 3 and approval under the internal name AMG 416, launching it commercially as Parsabiv. Amgen remains the current manufacturer and marketer in the US, EU and other markets. Per FDA Orange Book listings, the drug's formulation patents run into 2034 and Amgen has pursued patent litigation against at least one would-be generic manufacturer; no generic version is available as of this review. It sits alongside oral cinacalcet (now genericized) as one of a small number of drugs actually approved for secondary hyperparathyroidism on hemodialysis. There is no wellness, bodybuilding or grey-market interest in etelcalcetide of any kind we could find — an entirely conventional, clinic-administered nephrology drug.